Alantra advises NeoHealthHub on its merger with Germany’s PharmaLex

Oct 2022

Sell-side advisory

London – Alantra, the global investment banking and asset management specialist, has advised the shareholders of NeoHealthHub Limited, a pharmaceutical and healthcare services consultancy, on its merger with PharmaLex Group. Germany-based PharmaLex is a leading provider of specialised services for the pharma, biotech and MedTech industries worldwide.

Founded in 2013, NeoHealthHub (NHH) supports its customers by offering innovative and comprehensive market access, data and capability development solutions across all phases of the pharmaceutical and healthcare brand lifecycle through its four business units – NeoNavitas, NeoN, NeoSypher and NeoOptima.

NHH has its headquarters in Lutterworth, Leicestershire, employing around 50 people who provide their expertise to a diversified and loyal client base through unique, customised solutions designed to achieve the best outcomes for each client, leveraging their deep understanding of the differing processes across the entire UK healthcare system.

The agreement with NeoHealthHub will be an important step in building a pan-European market access practice covering major markets, including the UK, Germany, Italy, Spain, France and the Nordics.

This transaction marks a highly active period for Alantra in medical communications and consulting, having recently advised Strategic North on its sale to Prescient Healthcare Group and 90TEN on its sale to Envision Pharma; the management buy-out of Republic M! backed by Queen’s Park Equity; Prescient Healthcare Group and Helios on investment from Bridgepoint Development Capital and NorthEdge, respectively; and Bridgepoint on its acquisition of Fishawack Health.

Simon Doyle, CEO of NeoHealthHub, said, “The Alantra team were everything we could ask for in a trusted advisor – they understood our business model and the market dynamics, identified the key value drivers and provided the strategic guidance we needed to ensure a successful completion. We’ve achieved a great outcome with a partner who shares similar values and corporate culture and created an organisation that allows us to operate in a truly agile way, maximising opportunities as they emerge.”

Dr. Thomas Dobmeyer, CEO of Pharmalex said, “The merger with NHH is a welcome step for both our businesses and we are delighted to welcome the talented and knowledgeable team of market access, data and capabilities experts. By combining our expertise, we are better able to support our clients globally with their market access, data and capability needs and at the same time build a very successful local market access business that now includes the UK.”